Insights
Insights
HTA monthly – ISPOR 2026
Written by Paloma Charlesworth
Introduction
From the 17th–20th May 2026, the Professional Society for Health ...
HTA monthly – April updates
Written by Kiera Lander & Oliver Burn
1 - A NICE modular update: adopting the EQ‑5D‑5L UK value set
What is ...
HTA quarterly update
Written by Ben Clark, Paloma Charlesworth, and Kiera Lander
This quarterly update highlights recent ...
Accelerating hope? Optimising rare disease MHRA/FDA approval pathways and access strategy considerations
Written by Jo Wallis, Head of Commercialisation and Pricing Strategy
The recent developments put ...
The role of orphan drug designations in driving research and innovation for rare diseases
Written by Emma Bartram, Associate Systematic Review Analyst
A rare disease is one that affects fewer ...
HTA monthly update
By Toby Hobbs
Changes to NICE ICER thresholds confirmed
NICE has announced that from April 2026 there ...
Evaluating Health Inequalities: NICE’s Modular Update
Written by Paloma Charlesworth (Assistant Project Manager)
Background
Health inequalities are ...
HTA monthly – October 2025
By Kiera Lander
October brought real movement across the health technology assessment (HTA) landscape ...
RAISE guidance – maintaining SLR standards in an AI-assisted future
Written by Gwennie Ogilby (Associate Systematic Review Analyst) and Tom Metcalf (Senior Systematic Review ...
Thought Piece: How do we Reconcile Commoditisation and Strategic Value in Market Access?
Written by Dan Spacie, CEO of SCIRIS
Executive Summary
Market access services are undergoing a dual ...
Newborn genome screening: implications for health technology assessments of new orphan drugs
Written by Luke Parkes
Introduction
Newborn screening (NBS) is an impactful public health initiative ...
Navigating the complexities of economic evaluation for health technology assessment in dermatology
Written by Benjamin Clark
As the body’s largest organ, the skin is affected by a vast number of ...
No results found.